Is it too late to buy ResMed shares?

Do ResMed Inc. (ASX:RMD) shares offer investors value despite being a star performer on the S&P/ASX 200 (ASX:XJO) over the past 12 months?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc. (ASX: RMD) has been a star performer on the S&P/ASX 200 Index (ASX: XJO) over the past 12 months, with its share price up by 64%. With such a strong rise, do ResMed shares still offer investors value today?

ResMed growth story continues

ResMed continues to see strong improvement in its profit margins, driven by benefits from product mix changes and manufacturing and procurement efficiencies. Pleasingly, this indicates increasing economies of scale as the company further entrenches its already strong position in this niche of the market.

For the three months ended December 31, ResMed reported revenue growth of 13% to US$736.2 million. This took its half-year revenue ending December 2019 to US$1,417.2 million, which was up 14% over the prior corresponding period.

ResMed reported net operating profit growth of 26% to US$197.8 million for the second quarter, while for the first half, net operating profit was up by 22% coming in at US$368.9 million.

ResMed continues to see strong customer demand for its new products, particularly in masks and accessories. The potential market for sleep apnoea remains massive. It is estimated that there are one billion people impacted by sleep apnoea worldwide, and more than 80% of cases globally are actually undiagnosed.

ResMed's 'competitive moat' against other providers entering the market and attempting to gain market share is widening even further due to the reinvestment of a high proportion of its profits into research and development. It also plans to move further into the cloud-connected health space.

Less impacted than its peers in current ASX slide

ASX 200 healthcare shares such as Cochlear Limited (ASX: COH), Ramsay Health Care Limited (ASX: RHC) and Pro Medicus Limited (ASX: PME) have been hit quite hard in the current market crash, which has seen the Index fall more than 20% into a bear market.

ResMed shares have fared better in comparison. Although the ResMed share price has suffered falls, it has been relatively less impacted with a 10% fall from 20 February up until trading began today.

I think there are two key reasons for this this. Firstly, ResMed is seen as a very solid and stable share, with an entrenched market position and good growth prospects. Secondly, ResMed is likely perceived by investors as a company that will have a relatively low impact from the implications of the coronavirus.

Are ResMed shares a buy?

Despite the fact that the ResMed share price has delivered strong growth over the past 12 months, I still believe that ResMed offers investors good value today.

ResMed's growth potential over the next 12 to 24 months, in my view, still remains strong and with a correction to its share price recently, I think this adds to the appeal.

The company is also proving to be very resilient to all the current market turmoil, which could be an important asset if this volatility stays around over the next few months.

Phil Harpur owns shares of Cochlear Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended Cochlear Ltd., Ramsay Health Care Limited, and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »